Merck & Co., Inc. (MRK) To Present New Data For Investigational Hepatitis C Treatments MK-5172 And MK-8742 At EASL Annual Meeting/The International Liver Congress 2014
3/24/2014 7:41:59 AM
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new Phase 2 data for its two investigational hepatitis C virus (HCV) treatments - MK-5172, an investigational HCV NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor – are scheduled to be presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), also known as The International Liver Congress™ 2014. The data are from Merck’s overall Phase 2 clinical program. The meeting will take place in London, United Kingdom, April 9 - 13, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by